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followed by ﬁve years of Tamoxifen. She was thought to be with no
evidence of disease from her breast cancer. The patient presented to
her primary care physician complaining of abdominopelvic pain and
soreness. An abdominal and pelvic ultrasound revealed a 15cmcomplex
right lower quadrant mass. Follow-up CT scan revealed a markedly
enlarged uterus with an ill deﬁned right adnexal/lower quadrant mass
contiguous with the uterine fundus suggestive of possible sarcoma
(Fig. 1). CA-125 was noted to be 407. She was referred to Gynecologic
Oncology for deﬁnitive surgical management. The patient underwent
a diagnostic laparoscopy, exploratory laparotomy, radical hysterectomy,
bilateral salpingo-oophorectomy, debulking, omentectomy, and exten-Introductionthe fundus. Frozen section returned poorly differentiated carcinoma ofPrimitive neuroectodermal tumors (PNETs) were ﬁrst described in
1973 as a group of small round cell tumors that appeared to have
developed from neuroectodermal cells (Hart and Earle, 1973). This
group of tumors also includes Ewing sarcoma, rhabdomyosarcoma,
small-cell osteosarcoma, neuroblastoma, and hematolymphoid tumors
(Dehner, 1993). PNETs are usually seen along the central axis,
particularly in the soft tissue and bone structures of the chest and
abdomen of young adults and adolescents; predominately affecting
Caucasians and Hispanics. Small-cell carcinomas arising in the female
genital tract are rare (Kim et al., 2004). Early diagnosis is essential as
patients with non-metastatic disease respond relatively well to intense
multi-modality treatment (Grier et al., 2003).
Case
The patient is a 50 year old para 2 with a history of breast cancer
eight years prior to admission. She was treated with lumpectomy andilgore@utmck.edu (L.C. Kilgore),
u (M. Winkler),
. Open access under CC BY-NC-ND license. sive lysis of adhesions. A 15 cm necrotic mass was found arising from
unknown etiology. The uterine mass demonstrated multiple friable
tan-pink and hemorrhagic portions of tissue. The uterus contained
myometrium with diffusely inﬁltrative tumor without involvement of
the endometrium or serosal surface. The omentum was negative for
malignancy. Histologic sections of the debulked uterine mass and
myometrium involved by tumor demonstrated a poorly circumscribed
tumor with inﬁltrative borders containing poorly differentiated epi-
thelioid and spindle cells with a high nuclear/cytoplasm ratio and scant
cytoplasm (Fig. 2). The tumor also contained many areas of geographic
necrosis on examined sections. Several areas revealed tumor in an
angiocentric pattern giving the appearance of pseudorosettes. CD 99,
Fli-1, and Vimentin were positive on immunohistochemical stains
(Fig. 3). Final pathology revealed high-grade primitive neuroectodermal
tumor. The patient received 6 cycles of adjuvant carboplatin and
etoposide. Follow up CT scan showed no abnormalities and she remains
with no evidence of disease 16 months following completion of
treatment.Discussion
Primitive neuroectodermal tumors (PNETs) belong to a group of
small round cell tumors that are most commonly found in the central
nervous system, soft tissues, or bones (Kim et al., 2004). The most
common site of PNET in the female genital tract is the ovary (Odunsi
et al., 2004). PNET of the uterus, however, is rare, and has been reported
in less than 50 cases in the English literature (Bhardwaj et al., 2010). The
keywords “uterine” or “uterus” and “primitive neuroectodermal tumor”
were used in the PubMed search engine to ﬁnd a list articles reporting
Fig. 1. CT scan. Mass contiguous with the uterine fundus. Fig. 3. CD99 immunostain. Strong reactivity of neoplastic cells for this marker (400×).
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notably, Bhardwaj et al.'s article summarizes this list in their discussion.
Risk factors for uterine PNET are few, but include adolescent
or postmenopausal age, and Caucasian or Hispanic race. The most
common presenting symptom is abnormal vaginal bleeding, similar to
endometrial adenocarcinoma. However, in contrast to endometrial
cancer, which is typically detected in early stages, many uterine PNET
cases are diagnosed at advanced stages (Park et al., 2007). Interestingly,
this patient was premenopausal and presented with abdominopelvic
pain. She denied abnormal uterine bleeding.
The differential diagnosis of uterine PNETs include tumors exhibiting
neuroectodermal elements found in the central nervous system,
includingmature glial tissue of the endocervix or endometrium, imma-
ture teratoma with glial tissue, pure uterine gliomas, carcinosarcoma
with neuroectodermal differentiation, and retinal anlage tumor. The
diagnosis is based on light microscopic and immunohistochemical
evidence of neuroectodermal differentiation, with markers such as
CD99, FLi-1, and Vimentin (Park et al., 2007). CD99 is a highly speciﬁc
marker for PNET.
Von Hippel–Lindau disease (vHLD) has been associated with PNET
tumors. The ﬁrst description of the association of vHLD and a cerebellar
PNET occurred in 1993 (Becker et al., 1993). It was recently revealedFig. 2. H&E photo. High-power view of diffusely inﬁltrative epithelioid tumor cells with
few mitotic ﬁgures (400×).that chromosomal translocation t(11;22)(q24;q12), which fuses the
EWS gene on chromosome 22 and the FLI-1 gene on chromosome 11
and encodes a chimeric EWS/FLI-1 protein, occurs in most cases of
Ewing's sarcoma (Bernstein et al., 2006; Shulman et al., 2012). The
EWS gene can accidentally form fusion gene products with ERG, or
ETS-related gene, found in Ewing's sarcoma, which is similar in
morphology to PNET and other neuroendocrine tumors found in
vHLD. In fact, Shibanski et al. reported a rare case of mandibular ES
with chromosomal translocation t(21;22)(q22;q12) in which the EWS
gene is fused with the ERG gene on chromosome 21 (Shibanski et al.,
2013), while Dagher et al. found that 58 (76.3%) of 76 patients had
translocations (53 with the EWS/FLI-1 fusion transcript and 5 with the
EWS/ERG fusion transcript) (Dagher et al., 2001). Given this association
of vHLD and neuroendocrine tumors, genetic testing should be
considered if other risk factors are present.
Optimal treatment methods have not yet been established due to of
the rarity of these tumors. Treatment for PNETs has included surgery,
radiation, and chemotherapy alone, and multimodal therapy with
surgery, adjuvant chemotherapy, and radiation. The prognosis varies
depending on the age of the patient. Younger patients have a better
prognosis with 75% surviving at least 2 years compared with 32% in
the postmenopausal age group (Odunsi et al., 2004). When treated
with local control measures only (surgery and/or radiation therapy),
the disease has a high mortality rate and an 80–90% relapse rate.
Although overtmetastatic disease is found in fewer than 25% of patients
at the time of diagnosis, subclinical metastatic disease is assumed to be
present in nearly all patients due to this high relapse rate (Peres et al.,
2005). The utility of lymphadenectomy is unclear. Systemic chemo-
therapy has evolved as an important component of treatment. The use
of adjuvant chemotherapy began in the early 1970s and has resulted
in a marked improvement in outcome. Grier et al. published data from
a randomized trial showing improved ﬁve-year event-free survival
(69%) after the addition of etoposide and ifex to a standard regimen
in patients with nonmetastatic Ewing sarcoma, primitive neuroec-
todermal tumor of bone, and primitive sarcoma of bone. The standard
regimen of vincristine, doxorubicin, and cyclophosphamide produced
a ﬁve-year survival of 54%. Overall survival was also signiﬁcantly better
among patients in the groupwith etoposide and ifex (72%) versus those
without (61%). The most signiﬁcant side effects with the addition of
etoposide and ifex were infection, hemorrhage, and anemia requiring
more red-cell transfusions.
Morphologically, Ewing's sarcoma appears similar in appearance to
PNET. Published case series or reports of intracranial or spinal Ewing's
sarcomas have documented treatment using carboplatin and etoposide.
As such, platinum-based chemotherapy has been investigated for the
12 A.M. Dizon et al. / Gynecologic Oncology Reports 7 (2014) 10–12treatment for PNETs. Platinum based chemotherapy for PNET has
shown to have similar rates of survival to the much more toxic
regimens. Case reports have demonstrated long disease-free periods
after treatment with platinum and etoposide therapy alone (Tsai et al.,
2012). Also of note, treatment considerations for small cell and large
cell neuroendocrine carcinoma variants of the cervix take into account
the treatment options for cervical cancer, and draw on the data for
treating small cell lung cancer. Recent data supports the use of platinum
with or without etoposide in small cell and large cell neuroendocrine
carcinomas to improve survival (McCusker et al., 2003; Embry et al.,
2011).Conclusion
Primary PNET of the uterus is rare and requires early diagnosis and
treatment due to aggressive behavior of the tumor. Mortality can be
high despite a combination therapy approach. While there is no
consensus for the optimal chemotherapy treatment, carboplatin and
etoposide should be considered as a viable option.Disclaimer
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